Disclaimer: Preliminary results from this study were presented during the 17th and 18th World Conference on Lung Cancer -- IASLC (4--7 December 2016, Vienna, Austria, and 14--19 October 2017, Yokohama, Japan).

Introduction {#tca12967-sec-0005}
============

Malignant pleural mesothelioma (MPM) is an aggressive tumor associated with poor outcomes. Considered in the past as a rare disease, it has become more frequent in recent years.[1](#tca12967-bib-0001){ref-type="ref"} Occupational asbestos exposure is the principal risk factor for developing MPM, and explains the rise in incidence since the 1960s.[1](#tca12967-bib-0001){ref-type="ref"}, [2](#tca12967-bib-0002){ref-type="ref"} Although the use of asbestos has been banned in most European countries and the USA, it is still used in large amounts in underdeveloped countries, such as in Latin American. In fact, Brazil is one of the world\'s top asbestos producers, and mortality for MPM in Argentina and Brazil is dramatically increasing, reflecting the absence of regulatory laws in regard to asbestos.[3](#tca12967-bib-0003){ref-type="ref"}, [4](#tca12967-bib-0004){ref-type="ref"}

MPM is difficult to treat, because most patients have advanced disease at the time of diagnosis, conferring a poor prognosis. Median overall survival (OS) is approximately one year, and cure is rare.[5](#tca12967-bib-0005){ref-type="ref"}, [6](#tca12967-bib-0006){ref-type="ref"} Treatment options for patients with MPM include surgery, radiation therapy, and/or chemotherapy[7](#tca12967-bib-0007){ref-type="ref"}; however, for most patients, only palliative chemotherapy is possible due to the advanced disease at diagnosis.

The palliative effect of combination chemotherapy for patients with MPM has been documented previously.[8](#tca12967-bib-0008){ref-type="ref"}, [9](#tca12967-bib-0009){ref-type="ref"} The experience from the Royal Marsden Hospital focused on the palliative benefits of mitomycin C, vinblastine and cisplatin. That study demonstrated an objective response rate of 13.5%, with a median OS of 7 months, and 69% of patients reported some improvement of symptoms.[10](#tca12967-bib-0010){ref-type="ref"} In addition, another trial randomly compared first‐line (FL) chemotherapy (either mitomycin, vinblastine, cisplatin \[MVP\], or vinorelbine) with active supportive care[11](#tca12967-bib-0011){ref-type="ref"} although no OS benefit or improvement in quality of life was seen in the intention‐to‐treat population, exploratory analyses suggested a survival advantage for those treated with vinorelbine, with a two months survival benefit over active supportive care that approached statistical significance. Two large randomized trials have proved the benefit of the addition of a folate antagonist to cisplatin.[12](#tca12967-bib-0012){ref-type="ref"}, [13](#tca12967-bib-0013){ref-type="ref"} A large prospective trial including 456 patients comparing cisplatin alone with cisplatin and pemetrexed demonstrated a significantly better response rate (17% vs. 41%) and median OS (9.3 months vs. 12.1 months) with the cisplatin--pemetrexed combination over cisplatin alone.[12](#tca12967-bib-0012){ref-type="ref"}

The role of second‐line (SL) chemotherapy in MPM needs to be investigated. Pemetrexed alone or in combination with carboplatin has yielded objective responses of 18--21% in a small series of patients with disease progression after cisplatin chemotherapy.[14](#tca12967-bib-0014){ref-type="ref"} A prospective randomized phase III study enrolling 243 patients examined the role of pemetrexed versus best supportive care.[15](#tca12967-bib-0015){ref-type="ref"} That study demonstrated a better disease control rate for the pemetrexed arm (59% vs. 19%); however, there was no significant survival benefit. The survival results might have been influenced by post‐discontinuation chemotherapy, which was given to 28% of patients in the pemetrexed group and 51% of patients in the best supportive care group. The question of how to treat patients with progression after cisplatin and pemetrexed remains unanswered. Gemcitabine, vinorelbine, raltitrexed, oxaliplatin, nintedanib, and nivolumab have demonstrated activity when used in SL therapy and might be reasonable choices.[16](#tca12967-bib-0016){ref-type="ref"}, [17](#tca12967-bib-0017){ref-type="ref"}, [18](#tca12967-bib-0018){ref-type="ref"} The available scientific evidence about the clinical and pathological features related with survival in the Latin American population is scarce.

In this retrospective analysis, we characterized a group of patients with MPM from nine Latin American countries included in The MeSO‐CLICaP registry, describing the main pathological and clinical features, as well as clinical outcomes and factors related with survival.

Methods {#tca12967-sec-0006}
=======

The MeSO‐CLICaP registry identified 302 patients with advanced MPM from nine Latin American countries (Argentina, Brazil, Colombia, Costa Rica, Panamá, México, Perú, Nicaragua, and Venezuela) diagnosed and treated between January 2008 and March 2016. An institutional review board and privacy board waiver was obtained to facilitate retrospective collection of clinicopathological data (MeSO‐CLICaP Platform, Clínica del Country, Bogotá, Colombia). Data collected included age, sex, asbestos exposure, clinical manifestations, performance status, histology, disease stage, treatment modalities including chemotherapy (FL and beyond), and date of death or last follow up. Outcomes, such as progression free survival (PFS), overall survival (OS), and overall response rate (ORR) were recorded. The Cox model was applied to determine variables associated with survival. As these patients were not participants of a prospective protocol, imaging frequency was variable, and took place on average every two to three months. Patients with incomplete or unknown treatment data were excluded from treatment analyses.

This study was performed in accordance with the Declaration of Helsinki and the principles of Good Clinical Practice.

Random forest‐tree model design to predict response to FL chemotherapy in pleural mesothelioma among Latin American patients {#tca12967-sec-0007}
----------------------------------------------------------------------------------------------------------------------------

A random forest tree model was built for the prediction of response to FL chemotherapy among Hispanic patients with MPM. The variables included were sex, age, Eastern Cooperative Oncology Group (ECOG) performance status, smoking history, exposure to asbestos, and histology. Based on these characteristics, patients were classified as responders (partial or complete response) and non‐responders (stable disease or disease progression). In order to validate the results, a random subset of 70% of the sample was used to construct the model, and the remaining 30% was utilized as an independent validation cohort. Predictions were compared with each patient\'s treatment response and operational characteristics for the validation cohort model, and receiver operational curves were computed.

Statistical analysis {#tca12967-sec-0008}
--------------------

For descriptive purposes, continuous variables were summarized as arithmetic means and standard deviations. Categorical variables were reported as frequencies and proportions. Inferential comparisons were performed using Student\'s *t*‐test. The χ^2^‐test or Fisher\'s exact test were used to assess the significance among categorical variables. OS and PFS were estimated using the Kaplan--Meier Method. OS to FL, SL, and third‐line (TL) therapy were estimated since the date of treatment beginning until death or last follow up. PFS to FL, SL, and TL therapy was calculated from the date of treatment initiation until disease progression or last follow up.

Comparison among survival times was performed using the log--rank test or Breslow according to graphical assessment. A multivariate Cox proportional regression analysis was carried out to assess the independently associated factors with either OS or PFS. Statistical significance was considered when *P* ≤ 0.05 using a two‐sided test. All of the statistical analyses were performed using [spss]{.smallcaps} software version 23.0 (SPSS Inc., Chicago, IL, USA).

Results {#tca12967-sec-0009}
=======

Patient\'s characteristics {#tca12967-sec-0010}
--------------------------

Among the 302 patients included, the median age was 61.1 years (SD 10.6 years), 191 (63.2%) were men, 199 (65.9%) were ever smokers, and 117 (38.7%) had previous exposure to asbestos. A total of 228 patients (75.5%) had a baseline ECOG 0--1, 237 (78.5%) were epithelioid tumors, and 114 (37.7%) and 188 (62.3%) cases had stage III or IV MPM. Table [1](#tca12967-tbl-0001){ref-type="table"} shows the main characteristics of these patients.

###### 

General characteristics of patients (*n* = 302)

                                \% (*n*/*N*)
  --------------------------- ----------------
  Gender                      
  Female                       36.8 (111/302)
  Male                         63.2 (191/302)
  Age                         
  Mean (±SD)                    61.1 (10.6)
  \<60 years                   42.4 (128/302)
  ≥60 years                    57.6 (174/302)
  Smoking exposure            
  Current smoker               23.8 (72/302)
  Former smoker                42.1 (127/302)
  Never smoker                 32.8 (99/302)
  NA                            1.3 (4/302)
  Exposure to asbestos        
  Present                      38.7 (117/302)
  Absent                       46.7 (141/302)
  NA                           14.6 (44/302)
  ECOG status                 
  \<2                          75.5 (228/302)
  ≥2                           23.8 (72/302)
  NA                            0.7 (2/302)
  Histology                   
  Epithelioid                  78.5 (237/302)
  Sarcomatoid                   5.6 (17/302)
  Mixed                        10.6 (32/302)
  NA                            5.3 (16/302)
  Pleural effusion            
  Present                      75.5 (228/302)
  Absent                       14.2 (43/302)
  NA                           10.3 (31/302)
  Disease stage               
  III                          37.7 (114/302)
  IV                           62.3 (188/302)
  Main site of metastases\*   
  Liver                        12.8 (24/188)
  Bone                         12.8 (24/188)
  Lung                         68.1 (128/188)
  Other                         5.9 (11/188)

For variables (\*) denominator changes and percent is calculated only for those with a metastatic disease (stage IV). ECOG status, Eastern Cooperative Oncology Group performance status; NA, not available; SD, standard deviation.

FL therapy {#tca12967-sec-0011}
----------

Just 49 patients (16.2%) underwent pleurectomy, 57 (18.9%) received radiotherapy, 279 patients received platinum‐based chemotherapy in FL (plus pemetrexed 148/53% and gemcitabine 129/46.2%), and two patients received monotherapy (0.7%; Table [2](#tca12967-tbl-0002){ref-type="table"}). A total of 63 patients had pemetrexed maintenance (mean number of cycles 5.6 ± 3). The ORR to FL chemotherapy was 40.4% (complete response 4%/partial response 29.7%), and PFS was 5.7 months (95% CI 4.9--6.5; Fig [1](#tca12967-fig-0001){ref-type="fig"}a). In the univariate analysis, age \<60 years (8.7 vs. 5.0, *P* = 0.005), ever versus never smokers (6.7 vs. 4.9 months, *P* = 0.039), epithelioid versus *vs*. sarcomatoid or mixed histology (6.7 vs. 3.5 vs. 3.8 months, *P* = 0.001; Fig [1](#tca12967-fig-0001){ref-type="fig"}b) and pleurectomy (not reached vs. 5.1; *P* ≤ 0.001) were associated with better PFS in FL therapy. In the multivariate analysis age (HR 1.5, 95% CI 1.1--2.2, *P* = 0.039) and histology (HR 1.3, 95% CI 0.9--1.7, *P* = 0.001) were the only factors independently associated with PFS in FL therapy (Table [3](#tca12967-tbl-0003){ref-type="table"}). Median OS was 16.8 months (95% CI 13.0--20.5; Fig [1](#tca12967-fig-0001){ref-type="fig"}c). In the univariate analysis, ever versus never smokers (22.5 vs. 14.7 months, *P* = 0.005), a better ECOG performance status (\<2 vs. \>2; 18.4 vs. 13.5 months; *P* = 0.048), disease stage (III vs. IV; 20.7 vs. 14.6 months, *P* = 0.025), epithelioid versus sarcomatoid or mixed histology (20.7 vs. 13.4 vs. 14.7 months, *P* = 0.007; Fig [1](#tca12967-fig-0001){ref-type="fig"}d), pemetrexed maintenance (20.7 vs. 14.6 months, *P* = 0.051), and pleurectomy (22.4 vs. 14.9 months) were associated with better OS to FL therapy. Multivariate analysis demonstrated that disease stage (HR 1.6, 95% CI 1.1--2.4, *P* = 0.013) was the only independent prognostic factor for OS to FL treatment (Table [4](#tca12967-tbl-0004){ref-type="table"}).

###### 

Diagnosis and therapeutic intervention

                                                                                           *n*     \%
  -------------------------------------------------------------------------------------- ----- ------
  Pleurodesis for diagnosis and pleural effusion control                                   112   37.1
  Pleurectomy ± tumor decortication of the lungs for debulking and major cytoreduction      49   16.2
  Intensity‐modulated radiation therapy                                                     57   18.9
  First line chemotherapy (platinum base)                                                  279   92.4
  Platinum/pemetrexed ± bevacizumab[†](#tca12967-note-0005){ref-type="fn"}                 148   53.0
  Other combinations with platinum (gemcitabine)                                           129   46.2
  Monotherapy                                                                                2    0.7

Three patients received bevacizumab

![(**a**) Progression‐free survival (PFS) to first‐line (FL) therapy. (**b**) PFS to FL therapy according to histology. Histology, Epithelioid (![](TCA-10-508-g005.jpg "image")) 6.7 months (CI 95% 4.9--8.5), Sarcomatoid (![](TCA-10-508-g002.jpg "image")) 3.5 months (CI 95% 2.1--4.9) and Mixed (![](TCA-10-508-g003.jpg "image")) 3.8 months (CI 95% 3.3--4.4). (**c**) Overall survival (OS) to FL therapy. (**d**) OS to FL therapy according to histology. Histology, Epithelioid (![](TCA-10-508-g005.jpg "image")) 20.7 months (CI 95% 14.78--26.6), Sarcomatoid (![](TCA-10-508-g002.jpg "image")) 13.4 months (CI 95% 10.1--16.6) and Mixed (![](TCA-10-508-g003.jpg "image")) 14.7 months (CI 95% 9.7--19.6).](TCA-10-508-g001){#tca12967-fig-0001}

###### 

Univariate and multivariate analysis of the clinical factors associated with progression‐free survival to first‐, second‐, and third‐line treatment among patients with malignant pleural mesothelioma

                               PFS to first line   PFS to second line   PFS to third line                                                                                                                                   
  --------------------------- ------------------- -------------------- ------------------- ----------- ----------------- ------------- -------------------- ------------- ----------------- ------------- ----------------- -----------
  Overall                       5.7 (4.9--6.5)                                                          4.8 (3.9--5.6)                                                     5.3 (4.7--5.9)                                   
  Gender                                                                                                                                                                                                                    
  Female                        5.7 (4.8--6.7)                                                          4.8 (3.3--6.3)                                                     5.1 (4.5--5.6)                                   
  Male                          5.5 (4.3--6.7)           0.764                                          4.7 (3.6--5.8)       0.451                                         6.2 (3.9--8.5)       0.127                       
  Age                                                                                                                                                                                                                       
  \<60 years                    8.7 (4.9--12.5)                                                         6.4 (5.7--7.2)                                                     5.8 (5.2--6.4)                                   
  ≥60 years                     5.0 (4.3--5.7)         **0.005**         1.5 (1.0--2.2)     **0.039**   4.4 (4.0--4.8)     **0.042**      1.0 (0.7--1.6)        0.949      3.6 (1.9--5.3)       0.79                        
  Smoking exposure                                                                                                                                                                                                          
  Never smoker                  4.9 (4.5--5.5)                                                          4.8 (4.4--5.2)                                                     5.9 (1.4--10.3)                                  
  Ever smoker                   6.7 (4.2--9.1)         **0.039**         1.1 (0.7--1.7)       0.630     4.8 (3.3--6.4)       0.18         1.0 (0.6--1.7)        0.849      5.3 (4.5--6.1)       0.408                       
  Exposure to asbestos                                                                                                                                                                                                      
  Absent                        5.7 (4.9--6.6)                                                          5.8 (4.5--7.1)                                                     4.3 (2.6--5.9)                                   
  Present                       6.1 (4.5--7.7)           0.455                                          4.4 (3.9--5.0)       0.418                                             NR (NR)        **0.001**    0.2 (0.0--0.7)    **0.011**
  ECOG status                                                                                                                                                                                                               
  \<2                           5.5 (4.5--6.6)                                                          4.8 (3.8--5.7)                                                     5.9 (4.1--7.6)                                   
  ≥2                            5.7 (5.1--6.4)           0.944                                          4.6 (3.5--5.8)       0.693                                         5.3 (4.7--5.9)       0.763                       
  Disease stage                                                                                                                                                                                                             
  III                           5.4 (4.2--6.5)                                                          5.9 (4.9--6.9)                                                     9.8 (2.7--16.9)                                  
  IV                            5.7 (4.5--6.9)           0.437                                          4.6 (4.1--5.2)       0.528                                         5.3 (4.7--5.9)     **0.048**                     
  Histology                                                                                                                                                                                                                 
  Epithelioid                   6.7 (4.9--8.5)                                                          5.8 (4.9--6.7)                                                     5.9 (5.3--6.5)                                   
  Sarcomatoid                   3.5 (2.1--4.9)                                                          4.2 (3.5--4.9)                                                        2.9 (NR)                                      
  Mixed                         3.8 (3.3--4.4)         **0.001**         1.3 (0.9--1.7)       0.094     2.1 (0.6--3.6)    **\<0.001**   **1.9 (1.3--2.9)**    **0.001**       1.4 (NR)       **\<0.001**   6.5 (2.2--19.1)   **0.001**
  Pemetrexed maintenance                                                                                                                                                                                                    
  Absent                        6.1 (4.5--7.6)                                                          4.1 (4.0--4.2)                                                     7.8 (5.8--9.8)                                   
  Present                       5.4 (4.7--6.0)           0.353                                          5.9 (4.7--7.2)     **0.001**    **0.6 (0.4--0.9)**    **0.021**    5.3 (4.2--6.4)       0.998                       
  Pleurectomy                                                                                                                                                                                                               
  Yes                               NR (NR)                                                             6.1 (4.9--7.4)                                                         NR (NR)                                      
  No                            5.1 (4.5--5.7)        **\<0.001**                                       4.6 (3.9--5.4)     **0.036**      1.9 (0.9--3.6)        0.062      5.3 (4.5--6.1)       0.072      1.0 (0.3--3.7)      0.971
  Pleurodesis                                                                                                                                                                                                               
  yes                           6.7 (4.3--9.1)                                                          6.1 (3.5--8.7)                                                     5.3 (4.7--5.9)                                   
  no                            4.9 (4.4--5.6)           0.091           1.3 (0.9--1.8)       0.224     4.3 (3.8--4.9)    **\<0.001**     1.7 (1.1--2.8)      **0.026**    5.8 (0.0--12.4)      0.765                       
  Received radiotherapy                                                                                                                                                                                                     
  Yes                          10.4 (9.2--11.6)                                                         6.1 (4.7--7.6)                                                     5.3 (4.1--6.5)                                   
  No                            4.9 (4.6--5.1)        **\<0.001**        2.1 (1.3--3.4)     **0.002**   4.6 (4.3--4.9)       0.629                                         4.8 (3.4--6.1)       0.240                       
  ORR to first line                                                                                                                                                                                                         
  Yes                                 ...                                                               8.7 (6.2--11.3)                                                    6.2 (5.7--6.7)                                   
  No                                  ...                 ...                                           4.2 (3.7--4.6)    **\<0.001**   **2.9 (1.8--4.7)**   **\<0.001**   5.1 (4.0--6.1)       0.239                       
  ORR to second line                                                                                                                                                                                                        
  Yes                                 ...                                                                     ...                                                          9.8 (5.9--13.6)                                  
  No                                  ...                 ...                                                 ...             ...                                          3.8 (2.7--4.9)    **\<0.001**   2.5 (1.1--5.7)    **0.028**
  First line TTP ≥12 months                                                                                                                                                                                                 
  No                                                                                                    4.6 (4.1--4.9)                                                     5.3 (4.6--5.9)                                   
  Yes                                                                                                   6.1 (4.9--7.4)     **0.032**                                       9.8 (6.3--13.2)      0.488                       

Bold values represent *P* ≤ 0.05. 95% CI, 95% confidence interval; ECOG status, Eastern cooperative Oncology Group performance status; HR, hazard ratio; MPM, malignant pleural mesothelioma; NR, not reached; ORR, overall response rate (includes complete and partial response assesed by RECIST v1.1); TTP, time to progression.

###### 

Univariate and multivariate analysis of the clinical factors associated with overall survival to first, second and third line treatment among patients with malignant pleural mesothelioma

                                      OS           OS to second line   OS to third line                                                                                                                               
  --------------------------- ------------------- ------------------- ------------------ ----------- ------------------- ------------- ---------------- ------------- ------------------ ----------- ---------------- -----------
  Overall                      16.8 (13.0--20.5)                                                      14.6 (11.4--17.8)                                                9.9 (7.6--12.3)                                
  Gender                                                                                                                                                                                                              
  Female                       18.4 (11.9--24.9)                                                      15.1 (14.2--15.9)                                                 6.8 (6.4--7.2)                                
  Male                         15.5 (10.8--20.2)         0.789                                        11.3 (7.3--15.4)       0.822                                     9.9 (7.1--12.8)    **0.037**   1.3 (0.8--1.9)     0.261
  Age                                                                                                                                                                                                                 
  \<60 years                   20.7 (16.9--24.4)                                                      15.4 (14.4--16.5)                                                10.4 (8.6--12.2)                               
  ≥60 years                    14.7 (12.7--16.6)         0.222                                        10.9 (9.0--12.8)       0.204      0.9 (0.6--1.3)      0.855       5.9 (5.1--6.7)      0.09      0.9 (0.6--1.5)     0.901
  Smoking exposure                                                                                                                                                                                                    
  Never smoker                 14.7 (12.6--16.8)                                                      14.0 (10.4--17.7)                                                9.9 (5.2--14.7)                                
  Ever smoker                  22.5 (14.6--30.4)       **0.005**        0.7 (0.5--1.0)    **0.081**   15.1 (11.9--18.3)      0.229                                     9.9 (6.5--13.4)      0.062     0.9 (0.5--1.4)     0.549
  Exposure to asbestos                                                                                                                                                                                                
  Absent                       16.8 (9.6--23.9)                                                       14.3 (10.2--18.4)                                                 6.8 (5.9--7.7)                                
  Present                      20.0 (15.7--24.4)         0.285                                        15.9 (13.9--17.9)      0.521                                     10.3 (8.3--12.2)     0.08                      
  ECOG status                                                                                                                                                                                                         
  \<2                          18.4 (14.6--22.2)                                                      13.4 (9.6--17.3)                                                 9.9 (6.5--13.4)                                
  ≥2                           13.5 (11.4--15.6)      **0.048\***       1.4 (0.9--2.2)      0.098     15.1 (13.8--16.4)      0.542                                     8.1 (0.7--15.5)      0.545                     
  Disease stage                                                                                                                                                                                                       
  III                          20.7 (17.9--23.4)                                                      15.9 (14.5--17.3)                                                10.4 (6.2--14.6)                               
  IV                           14.6 (12.4--16.8)       **0.025**        1.6 (1.1--2.4)    **0.013**   11.9 (8.8--15.1)       0.079                                     8.0 (5.7--10.3)      0.091     1.7 (1.1--2.7)     0.023
  Histology                                                                                                                                                                                                           
  Epithelioid                  20.7 (14.8--26.6)                                                      15.2 (14.1--16.4)                                                9.9 (7.9--12.0)                                
  Sarcomatoid                  13.4 (10.1--16.7)                                                       9.8 (5.6--13.9)                                                     5.0 (NR)                                   
  Mixed                        14.7 (9.7--19.6)        **0.007**        1.4 (1.0--1.8)      0.187     14.0 (5.2--22.9)     **0.024**    1.4 (0.9--2.2)    **0.157**       11.7 (NR)         0.614                     
  Pemetrexed maintenance                                                                                                                                                                                              
  Absent                       14.6 (12.7--16.6)                                                      14.6 (11.9--17.3)                                                9.9 (9.2--10.7)                                
  Present                      20.7 (14.7--26.7)      **0.051\***                                     14.3 (9.5--19.1)       0.217                                     8.1 (4.2--12.1)      0.962                     
  Pleurectomy                                                                                                                                                                                                         
  Yes                          22.4 (14.3--30.5)                                                      11.0 (7.5--14.5)                                                 9.9 (7.5--12.4)                                
  No                           14.9 (11.0--18.9)       **0.041**        1.4 (0.9--2.3)      0.187     15.1 (12.7--17.5)      0.974                                     9.2 (6.2--12.2)      0.862                     
  Pleurodesis                                                                                                                                                                                                         
  Yes                          22.1 (18.7--25.6)                                                      15.4 (13.1--17.8)                                                10.3 (5.7--14.8)                               
  No                           14.2 (12.7--15.6)       **0.038**        1.4 (1.0--2.1)    **0.048**   11.9 (8.3--15.7)       0.066      1.4 (0.9--2.2)      0.125      8.1 (3.3--12.9)      0.175     1.3 (0.8--2.0)     0.270
  Received radiotherapy                                                                                                                                                                                               
  Yes                          20.0 (14.5--25.6)                                                      14.6 (9.3--19.8)                                                  6.8 (6.5--7.2)                                
  No                           14.2 (12.6--15.8)         0.420                                        12.2 (7.7--16.6)       0.925                                     8.1 (4.4--11.8)      0.815                     
  ORR to first line                                                                                                                                                                                                   
  Yes                          31.7 (27.9--35.4)                                                      17.4 (13.2--21.6)                                                10.3 (8.8--11.7)                               
  No                           13.5 (12.9--14.0)      **\<0.001**                                      9.9 (9.4--10.3)    **\<0.001**   2.6 (1.6--4.3)   **\<0.001**    6.5 (5.7--7.4)    **0.003**   2.2 (1.3--3.6)   **0.004**
  ORR to second line                                                                                                                                                                                                  
  Yes                          32.7 (31.0--34.3)                                                      22.5 (19.1--25.9)                                                11.4 (9.7--13.1)                               
  No                           14.9 (12.2--17.6)      **\<0.001**                                     10.1 (8.8--11.4)    **\<0.001**                                   6.8 (6.2--7.5)    **0.009**   2.6 (1.5--4.5)   **0.001**
  First line TTP ≥12 months                                                                                                                                                                                           
  No                           14.7 (12.7--16.6)                                                      12.2 (8.8--15.6)                                                 9.2 (5.9--12.5)                                
  Yes                          32.1 (20.5--43.6)      **\<0.001**                                     15.9 (14.6--17.2)   **0.020\***        ...             ...       9.9 (7.9--11.9)      0.319                     

Bold values represent *P* ≤ 0.05. 95% CI, 95% confidence interval; ECOG status, Eastern Cooperative Oncology Group performance status; HR, hazard ratio; MPM, malignant pleural mesothelioma; NR, not reached; ORR, overall response rate (includes complete and partial response assesed by RECIST v1.1); TTP, time to progression.

Prediction of response for FL chemotherapy {#tca12967-sec-0012}
------------------------------------------

The validated model obtained a sensitivity of 93% and a specificity of 95% for detecting responders and non‐responders to FL chemotherapy (Fig [S1](#tca12967-supitem-0001){ref-type="supplementary-material"}). The model yielded a receiver operator curve with a corresponding area under the curve of 0.98 (Fig [S2](#tca12967-supitem-0002){ref-type="supplementary-material"}). When predicted responders and non‐responders were compared, a survival benefit in terms of OS to FL and SL was observed (*P* \< 0.001 for both cases; Fig [S3](#tca12967-supitem-0003){ref-type="supplementary-material"}).

SL therapy and beyond {#tca12967-sec-0013}
---------------------

Of the 302 patients included, 126 (41.7%) received some treatment after FL, 98 patients (32.4%) achieved a response (partial response 39/12.9% and SD 59/19.5%), and 18 (5.9%) had a time‐to‐progression ≥8.0 months. Median PFS to SL therapy was 4.8 (95% CI 3.9--5.6; Fig [2](#tca12967-fig-0002){ref-type="fig"}a). Median OS to SL therapy was 14.6 months (95% CI 11.4--17.8; Fig [2](#tca12967-fig-0002){ref-type="fig"}b).

![(**a**) Median progression‐free survival (PFS) to second‐line (SL) therapy. (**b**) The median overall survival (OS) to SL therapy was 14.6 months (95% CI 11.4--17.8).](TCA-10-508-g004){#tca12967-fig-0002}

In the univariate analysis, the factors associated with better PFS to SL therapy were age \<60 years (6.4 vs. 4.4 months, *P* = 0.042), epithelioid versus sarcomatoid or mixed histology (5.8 vs. 4.2 vs. 2.1 months, *P* ≤ 0.001), pemetrexed maintenance (5.9 vs. 4.1 months, *P* = 0.001), pleurectomy (6.1 vs. 4.6 months, *P* = 0.036), and ORR to FL therapy (8.7 vs. 4.2 months, *P* ≤ 0.001). In the multivariate analysis, the factors independently associated with a better PFS after SL therapy were histology (HR 1.9, 95% CI 1.3--2.9, *P* = 0.001), and pemetrexed maintenance (HR 0.6, 95% CI 0.4--0.9, *P* = 0.021; Table [3](#tca12967-tbl-0003){ref-type="table"}). The median OS to SL therapy was 14.6 months (95% CI 11.4--17.8). In the univariate analysis, the factors associated with better OS after SL therapy were histology (epithelioid vs. sarcomatoid vs. mixed) (15.2 vs. 9.8 vs. 14.0 months, *P* = 0.024), ORR to FL therapy (17.4 vs. 9.9 months, *P* ≤ 0.001) and a time to progression above one year to FL therapy (15.9 vs. 12.2 months, *P* = 0.020). In the multivariate analysis, the ORR to FL therapy (HR 2.6, 95% CI 1.6--4.3, *P* ≤ 0.001) was the only independently associated factor with OS after SL therapy (Table [4](#tca12967-tbl-0004){ref-type="table"}).

A total of 81 patients (26.8%) received a TL therapy achieving a disease control rate of 67.4% and a PFS of 5.3 months (95% CI 4.7--5.9). In the multivariate analysis, the factors independently associated with PFS after TL therapy were exposure to asbestos (HR 0.2, 95% CI 0.0--0.7, *P* = 0.011), histology (HR 6.5, 95% CI 2.2--19.1, *P* = 0.001) and achieving an ORR to SL treatment (HR 2.5, 95% CI 1.1--5.7, *P* = 0.028; Table [3](#tca12967-tbl-0003){ref-type="table"}). OS to TL therapy was 9.9 months (95% CI 7.6--12.3). The ORR to FL (HR 2.2, 95% CI 1.35--3.6, *P* = 0.004) and ORR to SL (HR 2.6, 95% CI 1.5--4.5, *P* = 0.001) were independently associated factors for OS to TL therapy in the multivariate analysis (Table [4](#tca12967-tbl-0004){ref-type="table"}).

Discussion {#tca12967-sec-0014}
==========

Several prognostic factors have been identified for MPM, including older age, performance status, male sex, non‐epitheloid histology, among others, and prognostic scores systems derived from the combination of them have been proposed and accepted.[19](#tca12967-bib-0019){ref-type="ref"}, [20](#tca12967-bib-0020){ref-type="ref"} Meyerhoff *et al*. reviewed the outcomes of a large cohort of patients from the Surveillance, Epidemiology, and End Results Program, USA, database between 2004--2010 identifying that epithelioid tumors had better OS compared with biphasic and sarcomatoid histology types (14, 10, and 4 months, respectively, *P* \< 0.01). Similarly, surgical treatment only benefited patients with epithelioid histology (epithelioid MPM HR 0.72, *P* \< 0.01; biphasic MPM HR 0.73, *P* = 0.19; sarcomatoid MPM HR 0.79, *P* = 0.18), an outcome that consolidated the use of this intervention in this specific subgroup[5](#tca12967-bib-0005){ref-type="ref"}

In another population‐based registry, Linton *et al*. performed an analysis using the New South Wales Dust Diseases Board database during the period 2002--2009, finding 910 patients with MPM. In this large cohort, histology was also related with better survival (13.3 months for epithelioid histology vs. 6.2 months for sarcomatoid or biphasic, *P* \< 0.001).[6](#tca12967-bib-0006){ref-type="ref"} Other series also confirmed the prognostic role of histology.[21](#tca12967-bib-0021){ref-type="ref"}, [22](#tca12967-bib-0022){ref-type="ref"} In the present study, we have confirmed the prognostic relevance of histology, finding a median OS for epithelioid tumors of 20.7 months (95% CI 14.8--26.6). Our survival analysis showed a better outcome compared with other studies, probably because of the selection bias (considering that nearly all of our patients received a FL chemotherapy treatment compared with just 44% in the Linton *et al*. study); however, other series have identified a subgroup of patients with long survival (twice the median of 10 months) regardless of the treatment used, this observation suggests the presence of intrinsic factors that might modify main outcomes.[6](#tca12967-bib-0006){ref-type="ref"}, [12](#tca12967-bib-0012){ref-type="ref"}, [23](#tca12967-bib-0023){ref-type="ref"}

In our series, pemetrexed maintenance in addition to platinum in FL improved PFS, a conclusion previously described by others.[6](#tca12967-bib-0006){ref-type="ref"}, [12](#tca12967-bib-0012){ref-type="ref"} Since the Vogelzang *et al*. publication in 2003, platinum‐pemetrexed has been a common chemotherapy regimen for MPM; in our series, this was selected for 54% of patients, a frequency similar to data reported by studies from European countries and Australia.[10](#tca12967-bib-0010){ref-type="ref"} In most countries of Latin America, access to medicines for MPM, such as pemetrexed and bevacizumab, is limited. This is why almost half of our population received gemcitabine as part of the FL treatment. More efforts should be made to solve access limitations, and to improve the selection of patients according to the response profile and to the cost‐effectiveness of the interventions.

To optimize the selection of Latin American patients who are candidates for medical treatment for MPM in the FL and beyond, we designed and validated a model in our population to predict outcomes. Using age, performance status, and gender, we were able to predict the response and OS to FL chemotherapy with accuracy of 98%. This model has to be validated in other populations as a tool for treatment selection.

The better survival observed in our series can be explained by the proportion of patients treated with radical surgery (16.2%), or by the chemotherapy treatments, particularly those beyond FL (41.7% of patients received SL or TL chemotherapy) compared with other series. As we mentioned previously, other series have identified a group of patients with prolonged survival irrespective of the type of treatment received. If Latin American patients have genetic variations or molecular subtypes that influence survival, this is an issue that deserves to be further explored. ERCC1, PLK1 and miRNAs are some factors that have been studied and related with prognosis.[24](#tca12967-bib-0024){ref-type="ref"}, [25](#tca12967-bib-0025){ref-type="ref"} Furthermore, biomarkers, such osteopontin, mesothelin, and calretinin, may influence prognosis.[26](#tca12967-bib-0026){ref-type="ref"}, [27](#tca12967-bib-0027){ref-type="ref"}, [28](#tca12967-bib-0028){ref-type="ref"} It would be enriching to evaluate this data in the Latin American population with MPM, and analyze their influence on prognosis or prediction of response to treatment.

To the best of our knowledge, this is the largest series of MPM in the Latin American population, and reflects the real clinical scenario. This study has limitations regarding the selection of patients, and the fact that no molecular or biomarker analyses were performed, which would have been useful to explain some results obtained. In our series, patients had a good response to pemetrexed‐based chemotherapy, according to our results we can select patients who could derive more benefit of SL or even TL therapy based on clinical characteristics, such a performance status and response to FL chemotherapy. We advocate for a better treatment selection as a strategy to improve the cost‐effectiveness ratio in limited resources scenarios in Latin American countries.

Our study identifies factors associated with a clinical benefit from chemotherapy among Latin American patients with advanced MPM, and emphasizes the impact of histology and clinical benefit from chemotherapy on survival. SL chemotherapy appears to be active in Latin American MPM patients, particularly in younger patients with good PS and prolonged disease control with FL chemotherapy.
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**Figure S1.** Random tree model to predict the response to the first line in Hispanic patients with malignant pleural mesothelioma.
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Click here for additional data file.
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**Figure S2.** Receiver operator curve for the model to predict response to first line chemotherapy among Hispanic patients with malignant pleural mesothelioma.
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Click here for additional data file.

###### 

**Figure S3.** (**a**) Overall survival (OS) for first‐line (FL) therapy responders and non‐responders. (b) OS for second‐line (SL) therapy responders and non‐responders.
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Click here for additional data file.
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